Curium Pharma
France - ParisDiagnostics
Focus: Curium Pharma is a France-based nuclear diagnostics and radiopharmaceutical company founded in 2017, specializing in diagnostic imaging agents and therapeutic radiopharmaceuticals. The company operates in a niche but critical segment of pharmaceutical diagnostics with legacy and next-generation nuclear medicine products.
Profile data last refreshed 10h ago · AI intelligence enriched 3w ago
Open Jobs
0
About Curium Pharma
AI assessmentNot HiringNo open roles listed right now. Follow Curium Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Curium Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Declining
LOE Approaching
Legacy nuclear diagnostic agent facing imminent loss of exclusivity; likely generating moderate revenue but under patent/exclusivity pressure.
Help build intelligence for Curium Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.